Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the encouraging findings from the study, such as users noting that the vaccine shows a 68% protection against symptoms and a 90% rate against severe disease, which creates a sense of optimism. The terminology used, like 'encouraging' and 'light at the end of the tunnel,' reflects a hopeful outlook, while some responses suggest caution, emphasizing the need for more extensive trials due to prior concerns with adenovirus vectors. This mix of optimism and caution provides a balanced view of ongoing vaccine research.
Most posts show general support for the publication's findings, though some express skepticism.
Users demonstrate a strong curiosity about the vaccine's safety and effectiveness, indicated by multiple discussions around the results.
While many users share the publication, a few provide detailed commentary on the implications and necessity of further studies.
There is a widespread belief that this research could significantly influence future vaccine development and public health strategies.
Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objetivo (como todo fase 1) foi observar efeitos colaterais e dose, mas foi possível indiretamente avaliar eficácia. Bons resultados https://t.co/070IjTUaav
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/pNhPlj5x4K
Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/3tTqwP2MU7
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/83WlSEehqU
Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies, but the first week adverse reactions are important. https://t.co/qwyfncpq87 https://t.co/CEIqoQI3hd. @ANCAM_MEXICO @SIAC_cardio @smexcardiologia https://t.co/vd3ocoKsCB
Acabo este #hilo nidado de avances en la lucha contra #COVID19
In this video, we explore what we know about Sputnik V, the world's first COVID-19 vaccine. The focus is on safety and immune response, as many experts question its efficacy due to unconventional testing methods. Join…
Discover how the PiCoVacc inactivated vaccine candidate was developed in response to the urgent need for COVID-19 solutions. This video simplifies complex vaccine mechanisms and reviews systematic studies from global…
RT @bquindos: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, ope…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/6KphnOMi6T
@nytimes Delta & recombinant: neuronal metabolic addiction? Iperventilation waving protombina RTime? Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
@jonathanfdj @FerPauker @LassoGuillermo @UnionEuropeaRD A ver “abogado” con evidencia, publicado en lancet, protección contra síntomas 68%, contra enfermedad grave y hospitalización 90%, es mejor no opinar cuando no se sabe https://t.co/qhiS7lkv8h tú sigue sacando delincuente de las cárceles ahí está la fuente si acaso entiendes
@PabloRichly Me corrijo! Cansino publicó fase 1 /2 con adenovirus 5. https://t.co/nAJ9XbdewP
@ichbinschoener @VorsitzenderNAV @jensspahn @melanieleonhard https://t.co/XFcvFyjO5s die hier ca 100 Personen waren durchschnittlich 36 Jahre jung, ist also sicher kein Problem hochbetagte Menschen zu impfen
@AlberLeprinc @BousmahaWassel @brunotoucourt @Drzenattitude Oui oui, il y en a plusieurs dans le Lancet dont celle-ci, je vous invite à taper "covid19 vaccine" sur pubmed, c'est une sorte de moteur de recherche pour les études scientifiques https://t.co/SZfZlwxaJr
@Imam_Barbahari @UpNortWI https://t.co/c0qCfUEm47
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/ILCGPnaLCU
@hommel_b Wat een onzin. U koketteert graag met Engelstalige artikelen uit Lancet e.d. Ga eens naar PubMed en zoek uw eigen beweringen na. Ik geef u een voorbeeld. https://t.co/fhL1pUcYqu
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/LChTlbfqvq
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/hH9uGlRsRl
RT @javiersolana: The data of China vaccine. @TheLancet Safety, tolerability, and immunogenicity of a recombinant ad…
RT @javiersolana: The data of China vaccine. @TheLancet Safety, tolerability, and immunogenicity of a recombinant ad…
The data of China vaccine. @TheLancet Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non randomised, first-in-human trial. https://t.co/CBc9TM7c5x
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395: 1845-54. #Safety #Tolerability #I…https://t.co/DsH3sd8pGk
12/19:
The detailed methods of the assays have been reported previously - Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.https://t.co/mL56WPYrUe May 22, 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/47sxN6KGki
RT @SyedAAhmad5: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @SyedAAhmad5: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Phase 3 trials now underway in Brazil, South Africa, and the UK
RT @SyedAAhmad5: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet @TheLancet @UCHealthNews @uc_health https://t.co/hpgFKcHgPt
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/9wDoHLy7N8
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/J3uc2OPO3S
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/e8HkzgJjzw
Thanks to Aneesh Sharma for this great blog post on our journal club on 'Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine' https://t.co/5JnYwcABdV
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet https://t.co/iMK0wlHuCJ
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/9QiOKV2No1
Lancet 2020 Vol 395 P1845- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial 早い！と思ったらランセットに論文あったので読んでみました https://t.co/WqLsiFkJQ6
Brigter tomorrow for new vaccine rised in: : "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial" https://t.co/b4WPaFcb10
@annie_sparrow Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Published:May 22, 2020DOI:https://t.co/Wpi9arLeme https://t.co/wNWlqbpBrn
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/wNWlqbpBrn
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/iJJg01w10E
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/WXSvXxKfuB
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/B0DjIn00FD
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/xAabUwuHac
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial ... but experience from other diseases may caution the optimism yet... https://t.co/Vz1BJJrx4q @TheLancet https://t.co/OYMsfXhmGP
RT @profchloeorkin: 1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase…
RT @profchloeorkin: 1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase…
1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase II -However use of Ad5 vector concerning ...in HIV vac trials, pre-existing immunity assoc w’ HIV acquisition. https://t.co/63UtABgc1C
ECA Fase I => Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-In-Human Trial https://t.co/ILCGPnaLCU
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/Pd1WhM6gGg
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/hx91wlrPpY
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/a7fWU9uRff
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet 新型コロナウイルスのワクチン試験 第1相試験 非盲検 非ランダム 人では初？ https://t.co/Yr1OJFMaOZ
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/3tTqwP2MU7
多分ですが、これが該当記事 Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/S9aL3QLWfQ
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial #covid19rftlks https://t.co/Dv1HSJtSmX
[Articles] Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/09EesN2ZYY
RT @NewsNeus: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, o…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/5GWesnvugK
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. https://t.co/g2xGWdY59p
RT @JHSPH_NCRC: Zhu et al @TheLancet : First published report of a Phase I clinical trial for #SARSCoV2 #vaccine, which means there were no…
Zhu et al @TheLancet : First published report of a Phase I clinical trial for #SARSCoV2 #vaccine, which means there were not many people in the study and they were healthy volunteers. Results encouraging, but will need phase II and III trials to know more. https://t.co/OLuSNSZFKv https://t.co/b5uzo5ef2a
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/JoQF995wtC
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/83WlSEehqU
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID19 #vaccine : a dose-escalation, open-label, non-randomised, first-in-human trial - @TheLancet https://t.co/ovamFK70uA
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/iWDWYRXE8r
Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine https://t.co/AX4P6mh8T8 vía @practiceupdate
RT @hserag: Will Trump buy the vaccine from China for Americans? Safety, tolerability, and immunogenicity of a recombinant adenovirus type…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/uQvFYJeath
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/5FqVcmBCpA
|･ω･｀)ﾌﾑ Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet - https://t.co/ZBZQSPEVLp
RT @KoffiSodokin: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/Zwy8YvAkuS
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial @TheLancet
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @StefaniaArciell: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalati…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/30HjEPJuW9
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @sminaev2015: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/pNhPlj5x4K
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/f8ZpMu7Igd https://t.co/dsyi2mSLyO
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/krQ3TYt2UA
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/UrUisvSS9z
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/AXx9GbhzRJ
A phase 1 trial of a corona vaccine candidate. /// Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/HbIcpc22oo
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/zPSWD7BpXm
RT @paulcarald: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, o…
RT @paulcarald: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, o…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/jMMhGOq2Qp
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/5CVO7r6gyD
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine. https://t.co/VbbtUvlhKg
Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus type-5 Vectored COVID-19 Vaccine: A Dose-Escal… https://t.co/olrthmkPvX
In an important paper in The Lancet, authors from China show the first published human data for a SARS-CoV-2 vaccine. This is an adenovirus vector vaccine. They measure strong adaptive immune responses, but less in those with baseline adeno antibodies. https://t.co/TOyUsvhaO4 https://t.co/Q8nq1sBYOC
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID… https://t.co/pNDWAIW9Mv
RT @BodyImpact2: Primeros reportes de VACUNA contra COVID19 elaborada por CanSino demuestran hasta un 75% de producción de Anticuerpos neut…
RT @BodyImpact2: Primeros reportes de VACUNA contra COVID19 elaborada por CanSino demuestran hasta un 75% de producción de Anticuerpos neut…
Primeros reportes de VACUNA contra COVID19 elaborada por CanSino demuestran hasta un 75% de producción de Anticuerpos neutralizantes, 9% de efectos secundarios incapacitantes(fiebre, mialgias, artralgias);en personas <60 años sin comorbilidades DOI: 10.1016/S0140-6736(20)31208-3 https://t.co/nuK9oO3SXK
RT @Pcasbri: Acabo este #hilo nidado de avances en la lucha contra #COVID19
RT @Pcasbri: Acabo este #hilo nidado de avances en la lucha contra #COVID19
RT @Pcasbri: Acabo este #hilo nidado de avances en la lucha contra #COVID19
RT @Pcasbri: Acabo este #hilo nidado de avances en la lucha contra #COVID19
RT @Pcasbri: Acabo este #hilo nidado de avances en la lucha contra #COVID19
Acabo este #hilo nidado de avances en la lucha contra #COVID19
中国のグループのワクチンレポート（https://t.co/XgYXut3DS6）。アデノウイルスベクターにコロナウイルスのスパイク蛋白を組み込んだもの。原理的な問題は、アデノとコロナの両方に対する免疫ができること。#新型コロナウイルス #ワクチン
Safety, tolerability, and immunogenicity of a recombinant #adenovirus type-5 vectored #COVID19 #vaccine a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/CopYrZT8Y0 @TheLancet https://t.co/BBcj13uODP
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
Zhu et al @TheLancet: first in man open label study of 108 people in Wuhan-China of vaccine against #SARS_CoV2: Ad5 vectored COVID-19 vaccine resulted in humoral immune response at 28 days, T cell response at 14 days. Needs RCT now DOI:https://t.co/i0ZmuAjVj0
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
https://t.co/uWXeknGXex https://t.co/X7suQ9xjwQ
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
DOI: 10.1016/S0140-6736(20)31208-3 3/3.
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
RT @gabrielaborray3: Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies,…
Research is on the right way!! Recombinant adenovirus-5 vectored #COVID-19 #vaccine: in 28 days 100% have anti bodies, but the first week adverse reactions are important. https://t.co/qwyfncpq87 https://t.co/CEIqoQI3hd. @ANCAM_MEXICO @SIAC_cardio @smexcardiologia https://t.co/vd3ocoKsCB
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
RT @mab_sp125: Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objet…
Hoje publicados resultados do estudo fase 1 da vacina chinesa (Beijing Institute of Biotechnology/CanSino). Principal objetivo (como todo fase 1) foi observar efeitos colaterais e dose, mas foi possível indiretamente avaliar eficácia. Bons resultados https://t.co/070IjTUaav
Hoy Lancet publicó un ensayo fase 1 con una vacuna contra #COVIDー19 #COVID19 con resultados alentadores, será posible que por fin se empiece a ver la luz al final del túnel. https://t.co/4nep5e2E9p https://t.co/iNw7INFEKI
BF
SM
CZ
LG
G
PB
D
IS
ID
S
PP
S
CS
DB
CB
KW
BM
DO
A
AG
JS
M
TP
TJ
JS
MG
LF
FZ
AN
SA
IR
MS
UM
V
DE
OT
JM
Dʻ
JC
นก
LL
浅
AL
CK
CH
PS
H
SI
HP
YB
O
PS
GÖ
猫
BF
T
MG
R
青
E
NL
JM
PC
JN
SL
MM
F
N
WH
JS
EQ
IC
NM
AH
AG
JB
AD
CR
GT
SW
SC
TP
DB
C
AP
G
S
AB
PZ
SA
S
C
JK
WS
DB
TV
PF
PS
LG
PC
JR
VC
JM
AM
M
IH
LT
BI
RD
NG
C
K
加
PP
D
C
AM
C
AO
NB
DD
G
VC
VV
A
RC
MG
O
MF
S
PF
IM
E
JR
JP
TG
IB
WC
E
SK
DA